Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

被引：0

作者：

Caffo, O. ^{[1
]}

Biasco, E. ^{[2
]}

Facchini, G. ^{[3
]}

Fratino, L. ^{[4
]}

Gasparro, D. ^{[5
]}

Mosillo, C. ^{[6
]}

Maruzzo, M. ^{[7
]}

Santini, D. ^{[8
]}

Tucci, M. ^{[9
]}

Ortega, C. ^{[10
]}

Verderame, F. ^{[11
]}

Scagliarini, S. ^{[12
]}

Lo Re, G. ^{[13
]}

Procopio, G. ^{[14
]}

Fornarini, G. ^{[15
]}

Campadelli, E. ^{[16
]}

Sabbatini, R. ^{[17
]}

Maines, F. ^{[1
]}

De Giorgi, U. ^{[18
]}

机构：

[1] Santa Chiara Hosp, Trento, Italy

[2] Osped Santa Chiara, Pisa, Italy

[3] IRCCS, Fdn G Pascale, Ist Nazl Tumori, Naples, Italy

[4] Ctr Riferimento Oncol, Aviano, Italy

[5] Azienda Osped Univ, Parma, Italy

[6] Univ Roma La Sapienza, Rome, Italy

[7] Ist Oncol Veneto, Padua, Italy

[8] Univ Campus Biomed, Rome, Italy

[9] Osped San Luigi, Orbassano, Italy

[10] IRCCS, Candiolo, Italy

[11] Osped Villa Sofia Cervello, Palermo, Italy

[12] Osped Cardarelli, Naples, Italy

[13] Osped Santa Maria Angeli, Pordenone, Italy

[14] Fdn Ist Nazl Tumori, Milan, Italy

[15] Osped San Martino Genova, Genoa, Italy

[16] Osped Gen, Lugo Di Romagna, Spain

[17] Azienda Osped Univ, Modena, Italy

[18] IRST, Meldola, Italy

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw334.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

C09

引用

页数：1

共 50 条

[21] Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Oh, William K.
Miao, Raymond
Vekeman, Francis
Sung, Jennifer
Cheng, Wendy Y.
Gauthier-Loiselle, Marjolaine
Dhawan, Ravinder
Duh, Mei Sheng
MEDICAL ONCOLOGY, 2017, 34 (09)
[22] Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.
Maines, Francesca
De Giorgi, Ugo
Facchini, Gaetano
Fratino, Lucia
Gasparro, Donatello
Alesini, Daniele
Basso, Umberto
Tucci, Marcello
Ortega, Cinzia
Scagliarini, Sarah
Verderame, Francesco
Barni, Sandro
D'Angelo, Alessandro
Vicario, Giovanni
Donini, Maddalena
Carrozza, Francesco
Sava, Teodoro
Sirotova, Zuzana
Santini, Daniele
Caffo, Orazio
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[23] Oncological outcome of metastasis castration resistant prostate cancer (mCRPC) treated with new different agents sequencing in post-docetaxel: a retrospective study in Songklanagarind Hospital
Chaokhamin, Isaris
Bejrananda, Thanan Tanan
Attawettayanon, Worapat
Chalieopanyarwong, Virote
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 20 - 20
[24] Acitivity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.
Caffo, Orazio
De Giorgi, Ugo
Facchini, Gaetano
Fratino, Lucia
Gasparro, Donatello
Basso, Umberto
Alesini, Daniele
Tucci, Marcello
Ortega, Cinzia
Verderame, Francesco
Procopio, Giuseppe
Lo Re, Giovanni
Campadelli, Enrico
Omarini, Claudia
Donini, Maddalena
Morelli, Franco
Zucali, Paolo A.
Sartori, Donata
Conteduca, Vincenza
Galligioni, Enzo
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[25] Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis.
Caffo, Orazio
Kinspergher, Stefania
Maines, Francesca
Macrini, Sveva
Veccia, Antonello
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[26] Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)
Caffo, O.
Maines, F.
De Giorgi, U.
Fratino, L.
Lo Re, G.
Zagonel, V.
D'Angelo, A.
Donini, M.
Verderame, F.
Ratta, R.
Procopio, G.
Campadelli, E.
Massari, F.
Gasparro, D.
Ermacora, P.
Messina, C.
Giordano, M.
Alesini, D.
Conteduca, V.
Veccia, A.
Galligioni, E.
ANNALS OF ONCOLOGY, 2015, 26 : 61 - 61
[27] Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.
Antonarakis, Emmanuel S.
Goh, Jeffrey C.
Gross-Goupil, Marine
Vaishampayan, Ulka N.
Piulats, Josep M.
De Wit, Ronald
Alanko, Tuomo
Fukasawa, Satoshi
Tabata, Kenichi
Feyerabend, Susan
Berger, Raanan
Wu, Haiyan
Kim, Jeri
Poehlein, Christian Heinrich
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[28] Keynote-199: Updated analysis of Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel
Goh, Jeffrey C.
Antonarakis, Emmanuel S.
Gross-Goupil, Marine
Vaishampayan, Ulka N.
Piulats, Josep M.
de Wit, Ronald
Alanko, Tuomo
Fukasawa, Satoshi
Tabata, Kenichi
Feyerabend, Susan
Berger, Raanan
Wu, Haiyan
Kim, Jeri
Poehlein, Christian H.
de Bono, Johann S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 48 - 49
[29] Serum parathyroid hormone and calcium changes in metastatic castration resistant prostate cancer patients receiving enzalutamide in post-docetaxel setting.
Gernone, Angela
Pappagallo, Maria Nicla
Silvestris, Francesco
Silvestris, Franco
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[30] Treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis
Akaza, H.
Procopio, G.
Pripatnanont, C.
Facchini, G.
Fava, S.
Wheatley, D.
Leung, K. C.
Butt, M.
Silva, A.
Castillo, L.
Karavasilis, V.
Hitier, S.
Ecstein-Fraisse, E. B.
Bensfia, S.
Ozguroglu, M.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S492 - S493

← 1 2 3 4 5 →